Inconclusive evidence for non-inferior immunogenicity of two- compared with three-dose HPV immunization schedules in preadolescent girls: A systematic review and meta-analysis

Journal of Infection

Volumn 71, Issue 1, 2015, Pages 61-73

  Donken, Robine ^a,b   Knol, Mirjam J ^a   Bogaards, Johannes A ^a   van der Klis, Fiona R M ^a   Meijer, Chris J L M ^b   de Melker, Hester E ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antibodies; Human papillomavirus 16; Human papillomavirus 18; Human papillomavirus vaccine L1, type 16,18; Human papillomavirus vaccine L1, type 6,11,16,18; Immunization schedule; Non inferiority; Vaccination

Indexed keywords

WART VIRUS VACCINE; VIRUS ANTIBODY;

ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; CANCER INCIDENCE; CLINICAL TRIAL (TOPIC); DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG SAFETY; GROUPS BY AGE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; IMMUNIZATION; IMMUNOGENICITY; INCUBATION TIME; MEDICATION COMPLIANCE; MEMORY T LYMPHOCYTE; META ANALYSIS; PAPILLOMAVIRUS INFECTION; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UTERINE CERVIX CANCER; VIRUS NEUTRALIZATION; ADOLESCENT; ADULT; BLOOD; CHILD; COMPLICATION; FEMALE; IMMUNOLOGY; PAPILLOMAVIRUS INFECTIONS; PROCEDURES; UTERINE CERVICAL NEOPLASMS; VACCINATION; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; CHILD; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VACCINATION; YOUNG ADULT;

EID: 84930536912     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2015.02.005     Document Type: Review

References (43)

1. International Agency for Research on Cancer World cancer report 2008, [Report] Available from:, (Date last accessed 11-11-2014). http://www.iarc.fr/en/publications/pdfs-online/wcr/2008/index.php.
2. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch X.F., Kummer J.A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189(1):12-19.
3. Syrjanen K., Hakama M., Saarikoski S., Vayrynen M., Yliskoski M., Syrjanen S., et al. Prevalence, incidence, and estimated life-time risk of cervical human papillomavirus infections in a nonselected finnish female population. Sex Transm Dis 1990, 17(1):15-19.
4. Lehtinen M., Dillner J. Clinical trials of human papillomavirus vaccines and beyond. Nat Rev Clin Oncol 2013, 10(7):400-410.
5. European Medicines Agency Assessment report cervarix 2013, [Report] Available from:, (Date last accessed 24-8-2014). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-Variation/human/000721/WC500160885.pdf.
6. European Medicines Agency Assessment report gardasil 2014, [Report] Available from:, (Date last accessed 24-8-2014). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-Variation/human/000703/WC500170695.pdf.
7. Rothmann M., Wiens B., Chan I. Design and analysis of non-inferiority trials 2012, Chapman & Hall.
8. Jit M., Choi Y.H., Laprise J.F., Boily M.C., Drolet M., Brisson M. Two-dose strategies for human papillomavirus vaccination: how well do they need to protect?. Vaccine 2014, 32(26):3237-3242.
9. Apotheke Adhoc. Zwei-Dosen-Schema für HPV-Impfstoffe. Available from: (Date last accessed 7-8-2014). http://www.apotheke-adhoc.de/nachrichten/wissenschaft/nachricht-detail-wissenschaft/hpv-impfstoffe-zwei-dosen-schema-fuer-gardasil-und-cervarix/.
10. Dobson S. Two versus three doses of quadrivalent HPV vaccine: the immunogenicity study that could. Presented on August 24, 2014 in HPV Conference 2014 Seattle.
11. WHO SAGE Evidence based recommendations on Human Papilloma Virus (HPV) vaccines schedules 2014, [Report].
12. Romanowski B., Schwarz T.F., Ferguson L.M., Peters K., Dionne M., Schulze K., et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Hum Vaccin 2011, 7(12):1374-1386.
13. Dorleans F., Giambi C., Dematte L., Cotter S., Stefanoff P., Mereckiene J., et al. The current state of introduction of human papillomavirus vaccination into national immunisation schedules in Europe: first results of the VENICE2 2010 survey. Euro Surveill 2010, 15(47).
14. LaMontagne D.S., Mugisha E., Pan E., Kumakech A., Ssemaganda A., Kemp T.J., et al. Immunogenicity of bivalent HPV vaccine among partially vaccinated young adolescent girls in Uganda. Vaccine 2014, 32(47):6306-6311. EPub. 10.1016/j.vaccine.2014.08.071.
15. Altman D.G., Bland J.M. Interaction revisited: the difference between two estimates. BMJ 2003, 326(7382). p.219.
16. Cochrane Collaboration website.
17. Donken R., de Melker H.E., Rots N.Y., Berbers G.A., Knol M.J. Comparing vaccines: A systematic review of the use of the non-inferiority margin in vaccine trials. Vaccine 2015, 10.1016/j.vaccine.2015.01.072.
18. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyse. BMJ 2003, 327(7414):557-560.
19. Safaeian M., Porras C., Pan Y., Kreimer A., Schiller J.T., Gonzalez P., et al. Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial. Cancer Prev Res (Phila) 2013, 6(11):1242-1250.
20. Dobson S.R., McNeil S., Dionne M., Dawar M., Ogilvie G., Krajdenn M., et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA 2013, 309(17):1793-1802.
21. Lazcano-Ponce E., Stanley M., Munoz N., Torres L., Cruz-Valdez A., Salmeron J., et al. Overcoming barriers to HPV vaccination: non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months. Vaccine 2014, 32(6):725-732.
22. Romanowski B., Schwarz T.F., Ferguson L.M., Ferguson M., Peters K., Dionne M., et al. Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: results from a randomized study. Hum Vaccin Immunother 2014, 10(5).
23. Joura E.A., Kjaer S.K., Wheeler C.M., Sigurdsson K., Iversen O., Hernandez-Avila M., et al. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent vaccine 2008, 26(52):6844-6851.
24. Vink M.A., Bogaards J.A., van Kemenade F.J., de Melker H.E., Meijer C.J.L.M., Berkhof J. Clinical progression of high-grade cervical intraepithelial neoplasia: estimating the time to preclinical cervical cancer from doubly censored national registry data. Am J Epidemiol 2013, 178(7):1161-1169.
25. Herweijer E., Leval A., Ploner A., Eloranta S., Simard J.F., Dillner J., et al. Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma. JAMA 2014, 311(6):597-603.
26. Kreimer A.R., Rodriguez A.C., Hildesheim A., Herrero R., Porras C., Schiffman M., et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst 2011, 103(19):1444-1451.
27. Institut National De Santé Publique de Québec. HPV immunization of Québec pre-adolescents: Two or three doses? Available from: (date last accessed 16-12-2014). http://www.inspq.qc.ca/pdf/publications/1837_HPV_Immunization_PreAdolescents.pdf.
28. Pedersen C., Petaja T., Strauss G., Rumke H.C., Poder A., Richardus J.H., et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health 2007 Jun, 40(6):564-571.
29. Block S.L., Nolan T., Sattler C., Barr E., Giacoletti K.E., Marchant C.D., et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006 Nov, 118(5):2135-2145.
30. Naud P.S., Roteli-Martins C.M., De Carvalho N.S., Teixeira J.C., de Borba P.C., Sanchez N., et al. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination. Hum Vaccin Immunother 2014, 10(8).
31. Stanley M.A., Sudenga S.L., Giuliano A.R. Alternative dosage schedules with HPV virus-like particle vaccines. Expert Rev Vaccin 2014, 13(8):1027-1038.
32. Smolen K.K., Gelinas L., Franzen L., Dobson S., Dawar M., Ogilvie G., et al. Age of recipient and number of doses differentially impact human B and T cell immune memory responses to HPV vaccination. Vaccine 2012, 30(24):3572-3579.
33. Boxus M., Lockman L., Fochesato M., Lorin C., Thomas F., Giannini S.L. Antibody avidity measurements in recipients of Cervarix vaccine following a two-dose schedule or a three-dose schedule. Vaccine 2014, 32(26):3232-3236.
34. Mollers M., Scherpenisse M., van der Klis F.R., King A.J., van Rossum T.G., van Lochem E.M., et al. Prevalence of genital HPV infections and HPV serology in adolescent girls, prior to vaccination. Cancer Epidemiol 2012, 36(6):p519-24.
35. van der Klis F.R., Mollema L., Berbers G.A., de Melker H.E., Coutinho R.A. Second national serum bank for population-based seroprevalence studies in the Netherlands. Neth J Med 2009, 67(7):301-308.
36. Scherpenisse M., Mollers M., Schepp R.M., Boot H.J., Meijer C.J.L.M., Berbers G.A., et al. Changes in antibody seroprevalence of seven high-risk HPV types between nationwide surveillance studies from 1995-96 and 2006-07 in The Netherlands. PLoS One 2012, 7(11). p. e48807.
37. van Klooster T.M., Kemmeren J.A., van der Maas N.A., de Melker H.E. Reported adverse events in girls aged 13-16 years after vaccination with the human papillomavirus (HPV)-16/18 vaccine in the Netherlands. Vaccine 2011, 29(28):4601-4607.
38. Stokley S., Jeyarajah J., Yankey D., Cano M., Gee J., Roark J., et al. Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014-United States. MMWR Morb Mortal Wkly Rep 2014, 63(29):620-624.
39. Gasparini R., Bonanni P., Levi M., Bechini A., Boccalini S., Tiscione E., et al. Safety and tolerability of bivalent HPV vaccine: an Italianpost-licensure study. Hum Vaccin 2011, 7 Suppl: p. 136-146.
40. Einstein M.H., Baron M., Levin M.J., Chatterjee A., Edwards R.P., Zepp F., et al. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin 2009, 5(10):705-719.
41. Scherpenisse M., Schepp R.M., Mollers M., Mooij S.H., Meijer C.J.L.M., Berbers G.A., et al. Comparison of different assays to assess human papillomavirus (HPV) type 16- and 18-specific antibodies after HPV infection and vaccination. Clin Vaccine Immunol 2013, 20(8):1329-1332.
42. Mollers M., Vossen J.M., Scherpenisse M., van der Klis F.R.M., Meijer C.J.L.M., de Melker H.E. Review: current knowledge on the role of HPV antibodies after natural infection and vaccination: implications for monitoring an HPV vaccination programme. J Med Virol 2013, 85(8):1379-1385.
43. GlaxoSmithKline. Clinical study register. Study ID 115411. Available from: (Date last accessed 24-8-2014). http://www.gsk-clinicalstudyregister.com/study/115411%3Fcsrf_token=1398861437.11%23%2312fb16077d858694ad3b4fdad9fc54c849a8fbe5%26search_terms=hpv%26titles=%26study_ids=%26study_type=%26document_type=%26recruitment=%26conditions=%26compounds=%26lead=%26collaborators=%26gender=%26patient_level_data=%26age_from=%26age_from_type=%26age_to=%26age_to_type=%26first_receive_from=%26first_receive_to=%26last_updated_from=%26last_updated_to=%26country=%26state=%26search=Search#ps.